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Introduction
Drug-induced delirium is an adverse effect associated with a multitude of  
medications. It is most commonly occurs in elderly patients with as many 
as one in five hospitalized geriatrics experience delirium subsequent to 
medications [1-4]. However, it is important to note that drug-induced de-
lirium can occur at any age. Though reversible upon discontinuation of  
the offending agent(s), the occurrence of  delirium is known to increase 
hospital stays and mortality risk.
The pathophysiology of  drug-induced delirium has not been well estab-
lished and is suspected to be multifactorial. The dopaminergic, cholin-
ergic, GABAergic, serotonergic, and glutamatergic modulatory systems 
have all been proposed as possible pathways, but the exact pathophysiol-
ogy remains uncertain [1-3].   Most drugs known to induce or exacerbate 
delirium are thought to do so through one of  these pathways [2]. 
Promethazine exerts its effects by antagonizing to varying degrees his-
tamine 1, dopamine, alpha1 adrenergic, and muscarinic acetylcholine 
receptors [5-6]. Although it has multiple indications, promethazine is 
primarily used to manage nausea and vomiting. The antiemetic proper-
ties of  promethazine can be attributed in part to the blockade of  central 
dopamine and histamine receptors but is primarily associated with its 
anticholinergic properties.  Any anticholinergic medication in sufficient 
doses can potentiate a deleterious effect, but agents with affinity for the 
muscarinic receptors, as seen with promethazine, exert the strongest as-
sociation between medication use and delirium[3,5]. New memory acqui-
sition and stored memory retrieval is impaired, an action which is attrib-
uted to the cholinergic system’s influence on information processing [4]. 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to 
induce delirium as well[1,3-4]. The incidence appears to be the highest 
with indomethacin, but all NSAIDs can induce or exacerbate psychiatric 
symptoms, including delirium [3-4,7-8]. The pathophysiology of  NSAID 
induced psychiatric effects is not clearly established. It has been suggest-
ed that the chemical structure of  NSAIDs, particularly the indolic moiety 
of  indomethacin, is similar to that of  serotonin and therefore delirium 
occurs at least in part via the serotonergic pathway [3, 9]. The psychiatric 
effects abate when the offending agent is withdrawn and reappear when 
reintroduced, providing strong support that the effects are drug-induced 
[7-8].   Details of  ketorolac-specific induced behaviour change are scarce 
though the product labelling includes psychiatric symptoms as potential 
adverse effects.
Despite both agents being able to potentiate delirium, no known interac-
tion between promethazine and ketorolac has previously been thought to 
exist. The objective of  this case report is to describe a suspected synergis-
tic drug-drug interaction between promethazine and ketorolac presenting 
as drug-induced delirium.
Case Description
An 18 year old Caucasian female presented to the emergency room (ER) 
during the morning with a one day history of  nausea, vomiting, chills, 
and vague abdominal pain. She reported her vomit as greenish in color 
and non-bloody. There was no evidence of  fever, recent travel, contact 
with sick persons, or diet changes. She had been hospitalized approxi-
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mately six weeks prior for acute gastroenteritis but was otherwise healthy. 
The only medication she took as an outpatient was minocycline of  acne. 
The patient denied using illicit drugs, but admitted alcohol intake as re-
cently as two nights prior to admission.
The patient’s physical exam in the ER was normal except for some ab-
dominal tenderness and right sided guarding.  A complete metabolic 
panel (CMP) and complete blood count (CBC) were ordered on admis-
sion to the ER. The laboratory values were within normal limits with 
the exception of  hypokalemia (3.1 mEq/L), hyperglycemia (164 mg/dL) 
and an elevated white blood cell (WBC) count (12,400 cells/mL). Both 
the pregnancy test and urine drug screen conducted were negative. A 
urinalysis was also performed and did not indicate any abnormalities or 
infection. While in the ER, she received an injection of  promethazine 25 
mg. Approximately one hour after the promethazine administration she 
was noted to be thrashing and moving around in her bed. The move-
ments subsided and on the next assessment two hours later, the patient 
was observed to be resting quietly.
The patient was admitted to the hospital that evening for further evalu-
ation and orders for intravenous fluid replacement (Dextrose 5% and 
normal saline with 20 mEq potassium chloride) and promethazine 25 mg 
intravenously as needed for nausea and vomiting were written. Through 
the course of  the first night, the patient continued experiencing emesis 
despite two additional promethazine 25 mg injections. She was noted 
to be considerably anxious and periodically would thrash around errati-
cally in the bed. The patient was given a one-time intravenous dose of  
lorazepam 1mg which was successful in sedating the patient who rested 
comfortably for the remainder of  the night.  
After awakening the following morning, the patient once again experi-
enced continuous vomiting. She was given ondansetron which appeared 
to elevate her symptoms. The patient continued to complain of  abdomi-
nal pain and display left sided guarding. Though not febrile at admission, 
a temperature of  100.8º F (38.2°C) prompted a urinalysis, blood and 
urine cultures, and a computerized topography (CT) of  the abdomen, 
none of  which indicated infection or other abnormalities.  A CMP was 
also conducted that morning and all laboratory values were normal with 
the exception of  resolving hypokalemia (3.3 mEq/mL) for which she 
received potassium chloride 40 mEq by mouth. 
The patient received two additional doses of  promethazine for her 
continued nausea and vomiting. Her anxious and erratic behavior and 
abdominal pain also continued throughout the day.  Her nausea and 
vomiting was eventually controlled with the addition of  scheduled intra-
venous ondansetron 4 mg. Due to ongoing abdominal pain and nausea 
the evening of  the second night of  her hospital stay, the patient received 
an intravenous dose of  ketorolac 60 mg with her promethazine 25 mg 
injection. After the administration of  both agents, the patient’s behavior 
became even more increasingly erratic. She began thrashing around in 
her bed with more force than previously seen and attempted to disrobe 
and expose herself  to the nursing and medical staff  present.  The patient 
did not respond to nor elicit any verbal communication. This behavior 
continued until the early morning when the patient eventually fell asleep. 
The following morning, the patient stated that she had no recollection of  
this behaviour and appeared calm. The order for as need promethazine 
was discontinued, but the patient continued to receive the ondansetron 
which was successful in controlling her nausea and vomiting. After con-
sultations from surgery and gastroenterology, the patient was diagnosed 
with mild gastritis and duodenitis.
Because the patient did not have any known psychiatric history, her be-
haviour was suspected to be a result of  promethazine, ketorolac, or a 
combination of  both medications.  We did not suspect ondansetron or 
any drug-interaction involving ondansetron because the erratic behav-
ior appeared before the administration of  ondansetron, did not increase 
when ondansetron alone was added to promethazine, but did increase 
markedly when ketorolac was added to the promethazine regimen. Both 
promethazine and ketorolac were discontinued and no additional doses 
were administered. The patient did continue to receive the scheduled 
ondansetron which alleviated her symptoms. She did not exhibit any ad-
ditional abnormal behavior throughout the remainder of  her hospitaliza-
tion and was discharged on day four of  her hospital stay. 
Discussion
We present a case of  drug-induced delirium that presented following 
promethazine and ketorolac administration. Though the patient experi-
enced delirium-like symptoms following administration of  promethazine 
alone, her erratic behavior peaked following administration of  ketorolac. 
The patient did not have a history of  psychiatric illness other poten-
tial risk factors for delirium, such as infection, were not considered to 
be contributory to this patient’s altered behavior. Although the patient’s 
initial WBC was slightly elevated, she was correspondingly afebrile and 
had no other signs of  infection. The mildly elevated temperature on the 
second day of  admission was incidental with no additional supporting 
features of  infection. Furthermore, all symptoms resolved following the 
removal of  the offending agents thus supporting the suspicion that her 
delirium was drug-induced. It is possible that pain may have contributed 
to the patient’s delirium, but given the close proximity and consistency 
in delirium presentation following the administration of  promethazine 
and ketorolac; it was not thought to be a significant etiology. Our patient 
did receive a one-time dose of  lorazepam, also associated with delirium 
[3]. However, no delirious effects occurred following lorazepam, and the 
drug’s short duration and half-life make it an unlikely etiology for this 
patient’s symptoms. 
To our knowledge, this is the first report of  a drug-drug interaction be-
tween promethazine and ketorolac and the first clinical report of  delirium 
following ketorolac use. Because single pathophysiologic mechanisms of  
drug-induced delirium are not well understood, the influence of  concur-
rent action of  multiple pathways or multiple medications acting upon the 
same pathway cannot be well elicited. Since promethazine and ketorolac 
are thought to induce psychiatric effects via different pathways, it would 
be reasonable to consider that the interaction is synergistic. Several pub-
lished cases of  delirium occurred following supertherapuetic doses of  
promethazine, but delirious effects have been reported following thera-
peutic doses, as with our patient [5-6]. 
This report also involves drug-induced delirium associated with ke-
torolac, which has been reported in product labeling, but not detailed in 
readily available primary literature. All NSAIDs are thought to be able 
to induce or exacerbate delirium, though most cases have been associ-
ated with indomethacin [9]. Ketorolac is a pyrrole acetic acid derivative 
and structurally related to indomethacin [10]. Although a small lipophilic 
molecule, it is highly protein bound in plasma and does not distribute 
across the blood brain barrier (BBB) as readily as other agents within 
the class. Indomethacin’s penetration across the BBB is also thought to 
be less than other NSAIDs, but evidence indicates that efflux-proteins 
at the BBB help facilitate the transfer of  indomethacin into the central 
nervous system (CNS) [10]. The role of  transporters with ketorolac re-
mains unknown, but given the structural similarities between ketorolac 
and indomethacin, entrance into the CNS by transporters may explain 
the psychiatric adverse effects of  ketorolac (15).  Altered kidney function, 
which may associated with NSAID use, is also a risk factor for delirium. 
Our patient did not have any indications of  altered or changing kidney 
function throughout her hospital stay.
The emergence of  delirium in our patient following promethazine and 
ketorolac administration that subsided after the withdrawal of  both 
agents suggests a drug-drug interaction between two medications associ-
ated with psychiatric adverse effects not previously thought to interact. 
The only beforehand known drug-drug interaction producing psychiatric 
effects involving NSAIDs is an increased risk of  lithium toxicity second-
ary to a decreased renal clearance by NSAIDs. Our patient did not have a 
history of  lithium use nor received it while hospitalized. 
Conclusion
Promethazine and ketorolac are used together commonly in acute illness 
and it is possible that such an interaction occurs but is underreported. 
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Although not present in our patient, other risk factors for delirium, in-
cluding infection, pain, or altered kidney function may make it difficult 
to clearly associate delirium with the use of  these medications. Also, 
because the psychiatric effects of  promethazine are better understood, 
delirium presenting when these agents are used concurrently may be er-
roneously attributed to promethazine alone. Clinicians should be aware 
of  this potential effect and consider withdrawal of  both promethazine 
and ketorolac should psychiatric symptoms appear or are exacerbated in 
a patient receiving both agents concomitantly. 
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